Jefferson Einstein Infectious Diseases Fellowship
@einsteinphillyid.bsky.social
And that's a wrap for this week! Excited to hang out with applicants and keep learning.
Good luck and have fun, from all us at Jefferson Einstein.
Good luck and have fun, from all us at Jefferson Einstein.
September 12, 2025 at 3:36 PM
And that's a wrap for this week! Excited to hang out with applicants and keep learning.
Good luck and have fun, from all us at Jefferson Einstein.
Good luck and have fun, from all us at Jefferson Einstein.
Get out your Camera (2). This study published in 2020 (showed that combo therapy was not associated with improved outcomes and was stopped early due to increased adverse effects nephrotoxicity). So up front dual therapy not great. Salvage therapy though? Less clear jamanetwork.com/journals/jam...
Effect of Standard Therapy With vs Without an Antistaphylococcal β-Lactam on MRSA Bacteremia Outcomes
This randomized trial compares the effect of combining standard antibiotic therapy (intravenous vancomycin or daptomycin) with an antistaphylococcal β-lactam (intravenous flucloxacillin, cloxacillin, or cefazolin) vs standard therapy alone on a composite outcome of mortality, bacteremia, relapse, or...
jamanetwork.com
September 12, 2025 at 3:35 PM
Get out your Camera (2). This study published in 2020 (showed that combo therapy was not associated with improved outcomes and was stopped early due to increased adverse effects nephrotoxicity). So up front dual therapy not great. Salvage therapy though? Less clear jamanetwork.com/journals/jam...
Final case:
Patient with MSSA bacteremia who has difficult to clear MSSA bacteremia with no obvious drainable abscess. Pending TEE, should we be using combo therapy? Absolutely maybe perhaps totally! Lets look at the data.
Patient with MSSA bacteremia who has difficult to clear MSSA bacteremia with no obvious drainable abscess. Pending TEE, should we be using combo therapy? Absolutely maybe perhaps totally! Lets look at the data.
September 12, 2025 at 3:26 PM
Final case:
Patient with MSSA bacteremia who has difficult to clear MSSA bacteremia with no obvious drainable abscess. Pending TEE, should we be using combo therapy? Absolutely maybe perhaps totally! Lets look at the data.
Patient with MSSA bacteremia who has difficult to clear MSSA bacteremia with no obvious drainable abscess. Pending TEE, should we be using combo therapy? Absolutely maybe perhaps totally! Lets look at the data.
journals.asm.org/doi/10.1128/...
This paper breaks down the risk profile of different biologics for reactivation. As usual, TNF inhibitors are at the top of risk. B cell agents carry a minimal to non significant increase in risk Remember Hep B though!
This paper breaks down the risk profile of different biologics for reactivation. As usual, TNF inhibitors are at the top of risk. B cell agents carry a minimal to non significant increase in risk Remember Hep B though!
September 12, 2025 at 3:13 PM
journals.asm.org/doi/10.1128/...
This paper breaks down the risk profile of different biologics for reactivation. As usual, TNF inhibitors are at the top of risk. B cell agents carry a minimal to non significant increase in risk Remember Hep B though!
This paper breaks down the risk profile of different biologics for reactivation. As usual, TNF inhibitors are at the top of risk. B cell agents carry a minimal to non significant increase in risk Remember Hep B though!
Next up.
Patient with SLE presents to clinic after having positive Quantiferon in preparation for biologics, specifically Belimumab.What is the risk of reactivation of latent TB in patients starting B cell depleting therapy? I gotchu fam
Patient with SLE presents to clinic after having positive Quantiferon in preparation for biologics, specifically Belimumab.What is the risk of reactivation of latent TB in patients starting B cell depleting therapy? I gotchu fam
September 12, 2025 at 2:50 PM
Next up.
Patient with SLE presents to clinic after having positive Quantiferon in preparation for biologics, specifically Belimumab.What is the risk of reactivation of latent TB in patients starting B cell depleting therapy? I gotchu fam
Patient with SLE presents to clinic after having positive Quantiferon in preparation for biologics, specifically Belimumab.What is the risk of reactivation of latent TB in patients starting B cell depleting therapy? I gotchu fam
The clinical response to Gram stain–guided antibiotic therapy was noninferior to that of guideline-based antibiotic therapy (76.7% vs 71.8%). Gram stain–guided antibiotic therapy reduced the use of antipseudomonal agents and anti–methicillin-resistant Staphylococcus aureus agents. Nice!
September 12, 2025 at 2:24 PM
The clinical response to Gram stain–guided antibiotic therapy was noninferior to that of guideline-based antibiotic therapy (76.7% vs 71.8%). Gram stain–guided antibiotic therapy reduced the use of antipseudomonal agents and anti–methicillin-resistant Staphylococcus aureus agents. Nice!
August 7, 2025 at 2:10 PM